In this episode of Topical Conversations, Todd Schlesinger, MD, FAAD, FASMS, looks ahead to provide an overview of the exciting developments in skin cancer management that are on the horizon. 

Immunotherapy revolutionizing advanced nonmelanoma skin cancer treatment 

Immunotherapy has emerged as a game-changer in the treatment of patients with advanced nonmelanoma skin cancer (NMSC). This therapeutic approach has marked a substantial boon for dermatologists, offering new hope for patients with the most advanced cases of NMSC. 

New noninvasive options for low-risk skin cancer 

For low-risk skin cancer, further developments in photodynamic therapy (PDT) are eagerly anticipated. This noninvasive approach shows particular promise for patients with basal cell carcinoma (BCC) and potentially squamous cell carcinoma (SCC). 

Additionally, recent research has been published on the noninvasive management of low-risk BCC and SCC and focused on sparing patients from undergoing multiple surgeries. This reflects a significant shift in the approach to treating skin cancer, with an emphasis on minimizing invasive procedures while ensuring effective management. 

Key points 

• Immunotherapy is emerging as a transformative approach in advanced NMSC management 
• Developments in PDT are at the forefront of noninvasive options for low-risk skin cancer 
• Device- and energy-based treatments are anticipated as promising noninvasive options